Cara Therapeutics Inc
Cara Therapeutics Inc logo
CARA

Cara Therapeutics Inc (CARA)

$8.487.12%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$8.26
Day's Range
$9.28
$7.4
52-Week Range
$18.93
1 month return9.47%
3 month return27.31%
1 year return36.29%
5 year return34.51%

Company Information

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA™ has successfully completed a Phase 2 trial for the treatment of pruritus in patients with CKD and is currently in Phase 2 trials in atopic dermatitis, primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.
OrganizationCara Therapeutics Inc
Employees80
CEODerek Chalmers
IndustryHealth Technology

Analyst Recommendation

based on 14 analysts ratings

Buy
78%
Buy
21%
Hold
0%
Sell

Based on 14 Wall street analysts offering stock ratings for Cara Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 151.92%

Current

$9.13

Target

$23.0

Recommendation Trend

Based on 14 analyst

Current1M Ago3M Ago
Buy
11
11
11
Hold
3
3
3
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
541.3M
Book Value
4.25
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-1.74
PEG Ratio
0.0
Wall Street Target Price
25.86

Valuation

Trailing PE0.0
Forward PE0.0
Price/Sales (ttm)
23.5
Price/Book (mrq)
2.85
Enterprise Value
485.2M
Enterprise Value/Revenue
21.07
Enterprise Value/Ebitda
18.24

Technicals

Beta
1.09
50 Day MA
11.85
200 Day MA
13.04

Institutional Holdings

BlackRock Inc

13.43%

Vanguard Group Inc

6.05%

Farallon Capital Management, L.L.C.

4.66%

Disciplined Growth Investors Inc

3.16%

State Street Corporation

3.14%

Kingdon Capital Management LLC

2.21%

Discover more

Frequently Asked Questions

What is Cara Therapeutics Inc share price today?

Can Indians buy Cara Therapeutics Inc shares?

How can I buy Cara Therapeutics Inc shares from India?

Can Fractional shares of Cara Therapeutics Inc be purchased?

What are the documents required to start investing in Cara Therapeutics Inc stocks?

What are today’s High and Low prices of Cara Therapeutics Inc?

What are today’s traded volumes of Cara Therapeutics Inc?

What is today’s market capitalisation of Cara Therapeutics Inc?

What is the 52 Week High and Low Range of Cara Therapeutics Inc?

How much percentage Cara Therapeutics Inc is down from its 52 Week High?

How much percentage Cara Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Cara Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Cara Therapeutics Inc?